Liquid chromatography-tandem mass spectrometry for the quantification of ripretinib and its metabolites DP-5439 in human plasma.

ABSTRACT:

Background

Ripretinib, a broad-spectrum tyrosine kinase inhibitor, has been approved for the treatment of advanced gastrointestinal stromal tumors in adult patients. Clinical studies have shown that higher in vivo exposure of ripretinib correlates with improved efficacy, highlighting the potential clinical significance of therapeutic drug monitoring. In this study, a simple and stable liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was attempted to be established and validated for pharmacokinetic studies of ripretinib and its metabolite DP-5439 and therapeutic drug monitoring in human plasma.

Method

Ripretinib and DP-5439 were separated by chromatography using a Thermofisher Hypersil GOLD^TM C18 HPLC column. The mobile phase for gradient elu

SUBMITTER: Lin J 

PROVIDER: S-EPMC11743273 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature